Safety and Efficacy of Sublingual Immunotherapy for Allergic Rhinitis Due to Artemisia Annua

PHASE3CompletedINTERVENTIONAL
Enrollment

702

Participants

Timeline

Start Date

March 20, 2017

Primary Completion Date

October 22, 2017

Study Completion Date

October 30, 2017

Conditions
Allergic Rhinitis
Interventions
DRUG

AIT drops

once a day

DRUG

placebo drops

once a day

Trial Locations (13)

Unknown

Beijing Shijitan Hospital, Beijing

Beijing Tongren Hospital, Beijing

Peking University People's Hospital, Beijing

West China Hospital, Sichuan University, Chendu

Qingdao Municipal Hospital, Qingdao

No. 202 Hospital of PLA (General Hospital of Northern Theater Command ), Shenyang

First Hospital of Shanxi Medical University, Taiyuan

Second Hospital of Shanxi Medical University, Taiyuan

Tianjin Medical University General Hospital, Tianjin

The First Affiliated Hospital of Xinjiang Medical University, Ürümqi

Shaanxi Provincial People's Hospital, Xi'an

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

General Hospital of Ningxia Medical University, Yinchuan

All Listed Sponsors
collaborator

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

UNKNOWN

lead

Beijing Tongren Hospital

OTHER

NCT03990272 - Safety and Efficacy of Sublingual Immunotherapy for Allergic Rhinitis Due to Artemisia Annua | Biotech Hunter | Biotech Hunter